TIL: Instil Bio, Inc. Stock

by  •  • Comments Off on TIL: Instil Bio, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 82.40
Enterprise Value ($M) 158.60
Book Value ($M) 205.83
Book Value / Share 31.65
Price / Book 0.40
NCAV ($M) 60.55
NCAV / Share 9.31
Price / NCAV 1.36

Profitability (mra)
Return on Invested Capital (ROIC) -0.42
Return on Assets (ROA) -0.30
Return on Equity (ROE) -0.42

Liquidity (mrq)
Quick Ratio 14.19
Current Ratio 14.19

Balance Sheet (mrq) ($M)
Current Assets 161.03
Assets 306.30
Liabilities 100.48
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -90.54
Net Income -156.09

Cash Flow Statement (mra) ($M)
Cash From Operations -82.03
Cash from Investing 41.13
Cash from Financing 8.08

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
04-02 13G BML Investment Partners, L.P. 5.30

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-03-21 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI
2023-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-11-13 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUA
2023-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-07-26 389 3,998 9.73
2024-07-25 303 2,136 14.19
2024-07-24 733 1,690 43.37
2024-07-23 1,404 6,617 21.22
2024-07-22 694 2,446 28.37

(click for more detail)

Similar Companies
TGTX – TG Therapeutics, Inc. THAR – Tharimmune, Inc.
THTX – Theratechnologies Inc. TLSA – Tiziana Life Sciences Ltd
TNXP – Tonix Pharmaceuticals Holding Corp.


Financial data and stock pages provided by
Fintel.io